C4T will receive $35M incl. $10M up front & $25M one-time equity investment, ~$357M in milestones along with royalties on net sales in the licensed territories
Betta will lead the development, manufacturing & commercialization of CFT8919 (allosteric EGFR L858R degrader) in the licensed territories & is eligible to receive royalties on net sales outside of Greater China. C4T holds the right to develop & commercialize CFT8919 in all territories outside of Greater China
The IND application of CFT8919 is expected to be submitted to the US FDA in H1’23. CFT8919 is active in vitro and in vivo models of EGFR L858R-driven NSCLC in preclinical studies with broad coverage of on-target resistant mutations & intracranial activity
Ref: Globenewswire | Image: C4 Therapeutics
Related News:- Betta Pharma Licenses Inventisbio’s D-0316 to Treat Non-Small Cell Lung Cancer (NSCLC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
